Sun Yat-sen University
Clinical trials sponsored by Sun Yat-sen University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to outsmart resistant colorectal cancer Results expected Sep 2026 (estimated)
- Can adding linperlisib to standard chemotherapy improve outcomes in rare T-Cell lymphoma? Results expected Sep 2026 (estimated)
- 12-Week home workout aims to strengthen seniors with diabetes and muscle loss Results expected Sep 2026 (estimated)
- New triple therapy aims to shrink rectal tumors and avoid surgery Results expected Sep 2026 (estimated)
- New immunotherapy combo aims to boost hodgkin lymphoma remission Results expected Sep 2026 (estimated)
-
Experimental cell therapy targets Hard-to-Treat sarcoma
Disease control Stopped earlyThis phase 2 trial tested a new cell therapy called TAEST16001 in 8 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The therapy uses specially engineered immune cells to attack cancer cells that carry a specific marker (NY-ESO-1) in pa…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug combo for cervical cancer shows early promise, but trial halted
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Lung cancer drug trial halted early: what toripalimab Couldn't prove
Disease control Stopped earlyThis phase II trial tested whether the immunotherapy drug toripalimab could help patients with limited-stage small cell lung cancer stay cancer-free longer after standard chemoradiotherapy. The study planned to enroll 170 adults aged 18-75 who had not progressed after treatment. …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC